13D Filing: Aisling Capital III LP and Agile Therapeutics Inc (AGRX)

Page 9 of 11

Page 9 of 11 – SEC Filing

CUSIP No. 00847L100
SCHEDULE 13D
Page 9 of 11
Item 5.             Interest in Securities of the Issuer.
Item 5 is amended and restated in its entirety as follows:
(a),(b)

Reporting Person
Sole Voting
and Dispositive
Power
Shared Voting
and Dispositive
Power
Total Shares
% Ownership
Aisling Capital III, LP
1,304,933
0
1,304,933
3.8
Aisling Capital Partners III, LP
1,304,933
0
1,304,933
3.8
Aisling Capital Partners III LLC
1,304,933
0
1,304,933
3.8
Steve Elms
961
1,304,933
1,305,894
3.8
Dennis Purcell
1,879
1,304,933
1,306,812
3.8
Andrew Schiff
460
1,304,933
1,305,393
3.8
The aggregate percentage of shares of Common Stock reported as owned by each Reporting Person is based on 34,186,342 shares of Common Stock issued and outstanding, as of November 3, 2017, as reported in the Issuer’s Form 10-Q filed with the SEC on November 6, 2017.  Pursuant to the regulations promulgated under Section 13(d) of the Act, each of the Reporting Persons constitute members of a group and may be deemed to beneficially own an aggregate of 1,304,933 shares of Common Stock owned by the group, constituting approximately 3.8% of the outstanding shares of Common Stock.

Follow Agile Therapeutics Inc (NASDAQ:AGRX)

Page 9 of 11